1. Introduction {#sec1}
===============

Lymphoproliferative disorders include several well-recognized disease entities, defined by different cell origin, pathology, and prognosis. Immune dysregulation is thought to play a major role in lymphomagenesis as attested by the increased risk of certain lymphomas following organ transplantation, infections, immunodeficiency states, and autoimmune diseases or syndromes \[[@B1]--[@B3]\].

On the other hand, autoimmune diseases comprise a broad variety of conditions characterized by dysregulation of the immune response leading to the loss of tolerance to self-antigens. Diverse associations between malignancy and autoimmunity have been shown in multiple levels \[[@B2], [@B4]\]. In particular, the association between lymphomas and autoimmunity is well known several years ago, starting by observations that autoimmunity is often present in patients with non-Hodgkin lymphoma (NHL), mouse strains showing association between autoimmune disease and lymphoma, and epidemiologic evidence that autoimmune disorders carry a significantly increased risk of NHL development compared to healthy population \[[@B1], [@B5], [@B6]\]. Exploring the pathogenetic mechanisms of this association, recent data show that they might be bi-directional \[[@B7]--[@B9]\].

However, autoimmune rheumatic features and/or autoimmune phenomena occur frequently in the course of lymphoproliferative malignancies, and they may sometimes be the first sign of the malignancy \[[@B7]\]. However, to the best of our knowledge, multiple autoimmunity consisting of the presence of autoimmune haemolytic anaemia (AIHA), antimitochondrial antibodies (AMAs), and antiphospholipid antibodies (APLAbs) as the presenting manifestations of an extrahepatic B-NHL has not been previously described so far. Therefore, a representative case is reported herein, with an appropriate and extensive review of the literature.

2. Case Report {#sec2}
==============

A 63-year-old woman was admitted to our department because of fatigue, weakness and dysesthesias (numbness) of the lower limbs during the last two months but without fever. Physical examination revealed paleness, mild jaundice, and splenomegaly but no palpable peripheral lymph nodes and no neurological findings. Her family and past history were unrevealing.

Laboratory tests revealed severe anaemia, increased reticulocyte count, and elevated serum levels of indirect bilirubin, gamma-glutamyl-transpeptidase (*γ*-GT), immunoglobulin M (IgM), and lactate dehydrogenase (LDH) ([Table 1](#tab1){ref-type="table"}). The white blood cells (WBCs) and platelets (PLT) counts were within normal limits. Peripheral blood smear showed spherocytes and polychromatic red cells consistent with haemolysis. Direct and indirect Coombs\' tests were positive for immunoglobulin G (IgG) specificity, while a marked prolongation of activated partial thromboplastin time (aPTT) was obvious ([Table 1](#tab1){ref-type="table"}). Accordingly, a diagnosis of AIHA was made.

The presence of increased IgM levels in a female patient, along with the elevation of *γ*-GT on several occasions, prompted us to investigate for the presence of antimitochondrial autoantibodies (AMA), the hallmark for the diagnosis of primary biliary cirrhosis (PBC) \[[@B10]\]. Liver autoimmune serology detected AMA (titre 1/320; positive titre \>1/20) by indirect immunofluorescence (IIF) on in-house rat multiorgan substrate panel that included kidney, liver, and stomach as we published previously using standard protocols \[[@B10]\]. The AMAs were also detected twice by an enhanced performance M2 IgG-isotype-specific ELISA (30 units; UNL: 20 units) according to the manufacturer\'s instructions (ELISA; Quanta Lite, INOVA Diagnostics, San Diego, Calif, USA) and blotting using rat liver mitochondrial fractions \[[@B10]--[@B12]\]. Due to the prolongation of aPTT ([Table 1](#tab1){ref-type="table"}), investigation for lupus anticoagulant (LA), anticardiolipin antibodies (aCLAbs), and antibodies against *β*~2~-glycoprotein I (anti-*β*~2~-GPI) of IgM and IgG specificity was done, which revealed high positivity for APLAbs in two occasions ([Table 1](#tab1){ref-type="table"}), at least 12 weeks apart, as dictated by the revised classification criteria for the diagnosis of antiphospholipid syndrome (APLS) \[[@B13], [@B14]\]. Due to the above-mentioned findings as well as to the severity of AIHA, liver biopsy at this time point was considered unethical and was not performed.

In fact, both IgM and IgG aCL Abs as well as IgM anti-*β*~2~-GPI Abs were positive ([Table 1](#tab1){ref-type="table"}; ELISAs, INOVA Diagnostics, San Diego, Calif USA; cut-offs: 20 units).

A total-body computed tomography did not show abdominal or mediastinal lymphadenopathy. Serum protein electrophoresis and subsequent immunofixation revealed a monoclonal IgM light chain while bone marrow biopsy in combination with immmunohistochemical studies established the diagnosis of lymphoplasmacytic B-NHL ([Figure 1](#fig1){ref-type="fig"}).

Prednisolone (1 mg/kg/day) was started, and after a six-week course, haemoglobin, reticulocytes, and LDH levels had already become normal ([Table 1](#tab1){ref-type="table"}). In addition, till the time of this writing, the patient has received three cycles of chemotherapy every 28 days (500 mg rituximab, 2 mg bortezomib, and 16 mg dexamethazone). There was a marked clinical and laboratory improvement with absence of splenomegaly and decrease of IgM serum concentration ([Table 1](#tab1){ref-type="table"}) During the whole follow-up period (10 months), no thrombotic complication or development of clinical manifestations of PBC was noted though AMA and APLAbs remained steadily positive ([Table 1](#tab1){ref-type="table"}).

3. Discussion {#sec3}
=============

To the best of our knowledge, we describe herein for the first time the simultaneous detection of AMA and APLAbs in a patient with AIHA on the ground of systemic B-NHL.

The presence of AMA with anti-M2 antibody specificity is the major hallmark for the diagnosis of PBC \[[@B10], [@B15]\]. Actually, PBC diagnosis is usually based on the presence of at least 2 out of 3 of the following criteria: elevation of cholestatic enzymes, positive titre of AMA (titre ≥1/40), and characteristic liver biopsy \[[@B10], [@B15]--[@B17]\]. Clinically, the disease has a combination of characteristic symptoms including pruritus and profound fatigue though asymptomatic cases at the time of diagnosis are not infrequent as it is well known that even an isolated AMA positive test is indicative of early PBC and that silent disease eventually becomes clinically and biochemically evident up to 18 years after the first AMA screening \[[@B16]--[@B19]\]. In our case, the stable presence of AMA during followup rather excluded false positive serology during the acute setting of AIHA. However, it is not known whether PBC preceded NHL since they were diagnosed simultaneously.

Conflicting evidence exists regarding the association between PBC and NHL, while the presence of AMA without any clinical sign of liver disease, in patients with hematologic malignancies, has also been reported \[[@B6]\]. There are also several case reports linking PBC with NHL especially of the primary hepatic type \[[@B20]--[@B22]\]. However, a recent retrospective study by Panjala et al. \[[@B23]\] failed to confirm such an association since the estimated baseline risk of lymphoma in 2912 patients with PBC was as low as \<1%. Of note, the latter study showed that disease involvement was predominately extrahepatic, above the diaphragm \[[@B23]\]. There are also case reports of splenic lymphoma with hepatic infiltration presented as AMA-positive PBC \[[@B24]\]. However, neither the prevalence nor the clinical significance of AMA in hematologic malignancies with liver involvement has been estimated in large series.

APLAbs have been frequently associated with NHL as well as PBC \[[@B25], [@B26]\]. Their prevalence in patients with NHL varies from 26.6% to 41% \[[@B25], [@B27]\]. The pathogenicity of APLAbs in malignancy and in particular in NHL is not very clear: they do not seem to correlate with thrombotic events or other clinical manifestations of the APLS \[[@B25], [@B28]\], though thrombotic events associated with APLAbs can be the first manifestation of malignancy including NHL \[[@B29]\], while APLAbs have been suggested as independent prognostic factors in cases with aggressive NHL \[[@B27]\]. On the other hand, IgM and/or IgG aCLAbs have been detected in up to 40% of patients with PBC; they were associated with more severe disease, but they rather seem to be "nonpathogenic or nonthrombogenic" (anti-*β*~2~-GPI-independent) \[[@B25]\]. However, our patient was also IgM anti-*β*~2~-GPI Abs positive which means that the IgM aCLAbs were potentially "pathogenic or thrombogenic" (co-factor dependent), and therefore, a close followup for any clinical manifestation of the APLS seems mandatory.

Finally, it is well known that AIHA is highly associated with lymphoproliferative disorders \[[@B1], [@B5]--[@B7]\]. This frequent and close association makes the exclusion of lymphoproliferative disorders essential when AIHA is diagnosed \[[@B1], [@B5]--[@B7]\]. On the contrary, one of the many extrahepatic autoimmune manifestations that PBC has been linked to is AIHA, mainly in case reports \[[@B30]--[@B32]\].

Overall, all the above-mentioned data indicate that, in our patient, it is not clear whether the multiple autoimmune reactions with the simultaneous detection of APLAbs, AIHA, and AMA is the cause or the effect of the underlying lymphoproliferative disorder. Goodnow \[[@B33]\] described the pathways and genes likely to be involved in both autoimmune diseases and lymphomas, emphasizing that both types of diseases arise as a consequence of multistep processes that eliminate the checkpoints that inhibit uncontrolled B-cell growth, including uncontrolled growth of autoimmune lymphocytes. The most prominent example is the finding that somatic and germ-line Fas mutations, which presumably interfere with apoptosis, are associated with both autoimmune diseases and lymphomas in mice and in humans, while B-cell-activating factor of the TNF family (BAFF), which enhances survival of B cells, is found to be overexpressed in Sjogren\'s syndrome, rheumatoid arthritis, systemic lupus erythematosus, and lymphomas \[[@B34], [@B35]\].

In conclusion, our clinical case illustrates the possibility of a common pathogenetic pathway between the loss of tolerance to self-antigens leading to autoimmune phenomena and a lymphoproliferative disorder and raises, once again, the unanswered question of which is the cause and which the effect.

The authors wish to thank Dr. Maria Ioannou, Assistant Professor of Pathology for her study of the pathological evaluation of the bone marrow biopsy of the patient.

![Bone marrow biopsy: Infiltration by lymphoplasmacytic B-NHL. Hematoxylin-eosin staining (a). Immunohistochemical staining for anti-CD20 (b) and anti-CD 138 (c).](AD2011-841325.001){#fig1}

###### 

Patient\'s laboratory findings. Column A: on admission, column B: 6 weeks after initiation of prednizolone, column C: 1 month after the third cycle of chemotherapy (bortezomide, rituximab, and dexamethasone).

  --------------------------------------------------------------------------------------------------------------------------------------------------------
                              A       B      C                              A      B      C                                        A       B       C
  --------------------------- ------- ------ ------ ----------------------- ------ ------ ----- ---------------------------------- ------- ------- -------
  **WBC**\                    10,2    6,4    6,7    **Glucose**\            106    101    88    **IgG**\                           1220    967     1040
  (4,5--10,5 × 10^3^/*μ*L)                          (75--110 mg/dL)                             (847--1690 mg/dl)                                  

  **NE**\                     6,7     3,68   3,7    **Urea**\               46     20     27    **IgA**\                           299     290     161
  (1,5--6,5 × 10^3^/  *μ*L)                         (10--43 mg/dL)                              (99--300 mg/dl)                                    

  **LY**\                     2,9     2,32   2,9    **Creatinine**\         0,96   0,76   0,7   **IgM**\                           757     721     350
  (1,2--3,8 × 10^3^/  *μ*L)                         (0,66--1,1 mg/dL)                           (64--249 mg/dl)                                    

  **HCT**\                    17,5    43,5   43     **Total protein**\      7,1    8,1    7,2   **Direct Coombs\'test**            +++     ++      ++
  (36--46%)                                         (6,4--8,3 g/dL)                                                                                

  **HGB**\                    5,7     14,6   14,1   **Albumin**\            3,66   4,42   4,3   **Indirect Coombs\' test**         +++     ++      −
  (12--16,0 g/dL)                                   (3,5--5,2 g/dL)                                                                                

  **MCV**\                    120,6   92,2   89     **Total bilirubin**\    3,12   0,55   0,5   **Lac test**\                      1,98    2,42    2,55
  (79--98 fl)                                       (0--1,1 mg/dL)                              (0,8--1,2)                                         

  **RBC**\                    1,45    4,75   4,8    **Direct bilirubin**\   0,6    0,1    0,1   **C4**\                            \<1,4   \<1,4   8
  (3,8--5,4 × 10^6^/  *μ*L)                         (0,01--0,2 mg/dL)                           (10--40 mg/dl)                                     

  **RET**\                    346     102    86     **AST**\                26     18     18    **AMA^1^**                         1/320   1/160   1/160
  (20--160 × 10^3^/*μ*L)                            (0--31 IU/L)                                                                                   

  **PLT**\                    401     245    238    **ALT**\                5      12     36    **Anti-M2 IgG^2^**                 30      25      \<20
  (140--440 × 10^3^/  *μ*L)                         (0--34 IU/L)                                                                                   

  **ESR**\                    105     43     20     **γ**--**GT**\          40     54     176   **Anti**-**M2 IgA^3^**             502     304     \<20
  (0--20 mm)                                        (0--38 IU/L)                                                                                   

  **PT**\                     17,5    70,5   25     **ALP**\                80     110    137   **Anti-CL IgM^4^**                 \>130   \>100   94
  (9--14 sec)                                       (0--120 IU/L)                                                                                  

  **INR**\                    1,68    4,9    1,8    **CPK**\                32     23     10    **Anti-CL IgG^5^**                 30^6^   28^6^   35^6^
  (0,85--1,15)                                      (0--145 U/L)                                                                                   

  **aPTT**\                   77,1    77,5   99,6   **LDH**\                603    165    123   **Anti-β**~2~**-GPI IgM^6^**       179     62      40
  (25--35 sec)                                      (0--247 IU/L)                                                                                  

  **Fibrogen**\               309     271    256    **CRP**\                0,6    0,3    0,3   **Anti**-**β**~2~**-GPI IgG^7^**   \<20    \<20    \<20
  (180--440 md/dL)                                  (0,5 mg/dL)                                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------

WBC: white blood cells, NE: neutrophils, LY: lymphocytes, HCT: hematocrit, HGB: hemoglobulin, MCV: mean corpuscular volume, RBC: red blood cells, RET: reticulocytes, PLT: platelets, ESR: erythrocyte sedimentation rate, PT: prothrombin time, INR: international normalised ratio, aPTT: activated partial thromboplastin time, AST: aspartate transaminase, ALT: alanine transaminase, *γ*-GT: gamma-glutamyl transpeptidase, ALP: alkaline phosphatase, CPK: creatine phosphokinase, LDH: lactate dehydrogenase, CRP: C-reactive protein, Lac test: lupus anticoagulant test The rests abbreviations are same as in text; Parentheses show the normal range; ^1^indirect immunofluorescence (IIF), on in-house rat multiorgan substrate panel that include-kidney, liver, and stomach tissue. Positive titer \>1/20; ^2,3^M2-specific AMA by ELISA (Quanta Lite, INOVA Diagnostics, San Diego, Calif, USA); IgG-isotype AMA cut-off: 20 units; IgA-isotype AMA cut off: 217 optical density (OD).

^4,5,6,7^ELISAs (Quanta Lite, INOVA Diagnostics, San Diego, Calif, USA); cut-off of each ELISA: 20 units.
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